Please ensure Javascript is enabled for purposes of website accessibility


Big things are happening at Ogier. Change is embedded in everything we do. It is redefining our talent, our ways of working, our platforms of delivery, our culture.



We have the expertise to handle the most demanding transactions. Our commercial understanding and experience of working with leading financial institutions, professional advisers and regulatory bodies means we add real value to clients’ businesses.

View all services

Business Services Team

View all Business Services Team


Our sector approach relies on smart collaboration between teams who have a deep understanding of related businesses and industry dynamics. The specific combination of our highly informed experts helps our clients to see around corners.

View all sectors


Ogier provides practical advice on BVI, Cayman Islands, Guernsey, Irish, Jersey and Luxembourg law through our global network of offices across the Asian, Caribbean and European timezones. Ogier is the only firm to advise on this unique combination of laws.

News and insights

Keep up to date with industry insights, analysis and reviews. Find out about the work of our expert teams and subscribe to receive our newsletters straight to your inbox.

Fresh thinking, sharper opinion.

About us

We get straight to the point, managing complexity to get to the essentials. Our global network of offices covers every time zone. 

No Content Set

Ogier advises Summit Healthcare on its de-SPAC merger with YS Biopharma


21 March 2023

Hong Kong

Save as PDF

Ogier acted as Cayman Islands counsel to Nasdaq-listed SPAC Summit Healthcare Acquisition Corp in its de-SPAC merger with YishengBio Co Ltd, which was later renamed YS Biopharma Co Ltd.

Upon the completion of the de-SPAC merger on 16 March 2023, the shares and warrants of YS Biopharma commenced trading on the Nasdaq Global Market on 17 March 2023 (with the new ticker symbols YS and YSBPW respectively).

The business combination involved two consecutive Cayman Islands statutory mergers. As a result of the mergers, the existing shareholders or warrantholders of Summit Healthcare had their shares or warrants cancelled or converted in exchange for ordinary shares or warrants of YS Biopharma.

The Ogier team in Hong Kong was led by partner Florence Chan, with support from the firm's global head of Corporate Nathan Powell, senior associates Carmen Leung and Janice Chu. Ogier worked closely with Summit Healthcare's US counsel Cooley LLP in this de-SPAC transaction.

YS Biopharma is a global biopharmaceutical company focusing on new generations of vaccines and therapeutic biologics for infectious diseases and cancer.

No Content Set